PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
暂无分享,去创建一个
J. Schellens | J. Beijnen | I. Meijerman | S Harmsen | I Meijerman | R F Maas-Bakker | J H Beijnen | J H M Schellens | S. Harmsen | R. Maas-Bakker
[1] M. Barrand,et al. Signalling pathways influencing basal and H2O2‐induced P‐glycoprotein expression in endothelial cells derived from the blood–brain barrier , 2003, Journal of neurochemistry.
[2] Suneet Shukla,et al. Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2 , 2009, Drug Metabolism and Disposition.
[3] B. Sarkadi,et al. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[4] J. Schellens,et al. Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction , 2008, Drug Metabolism and Disposition.
[5] G. Szakács,et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.
[6] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[7] R. Rotem,et al. Protein kinase C ε mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells , 2002 .
[8] J. Schellens,et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP , 2012, Investigational New Drugs.
[9] Jubilee Brown,et al. In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines , 2008, Cancer Chemotherapy and Pharmacology.
[10] J. H. Beijnen,et al. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor , 2009, Cancer Chemotherapy and Pharmacology.
[11] B. Haehner‐Daniels,et al. The effect of rifampin administration on the disposition of fexofenadine , 2001, Clinical pharmacology and therapeutics.
[12] R. Kim,et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects , 2003, Clinical pharmacology and therapeutics.
[13] Zhe-Sheng Chen,et al. ABCC10, ABCC11, and ABCC12 , 2007, Pflügers Archiv - European Journal of Physiology.
[14] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[15] A. Dantzig,et al. Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979 , 2003, International journal of cancer.
[16] Zhe-Sheng Chen,et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.
[17] C. J. McGrath,et al. Effect of exchange rate return on volatility spill-over across trading regions , 2012 .
[18] Oliver Burk,et al. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin* , 2001, The Journal of Biological Chemistry.
[19] Adorjan Aszalos,et al. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. , 2007, Drug discovery today.
[20] A. Collett,et al. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? , 2004, Biochemical pharmacology.
[21] J. Schellens,et al. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line , 2009, Cancer Chemotherapy and Pharmacology.